Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis.
Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis.
复制标题
DOI：
10.1002/acr.24529
复制
发表时间：
2022-07
影响因子：
4.7
通讯作者：
PRCSG Advisory Council and the CARRA Executive Committee
中科院分区：
文献类型：
--
作者：
Weiss PF;Fuhlbrigge RC;von Scheven E;Lovell DJ;Colbert RA;Brunner HI;PRCSG Advisory Council and the CARRA Executive Committee
本综述将总结附着点炎相关关节炎（ERA）伴轴向受累的儿童与非影像学（某些情况下为影像学）轴向脊柱关节炎（SpA）的成人之间以及ERA伴主要外周疾病表现的儿童与外周SpA的成人之间共有的临床、遗传和病理生理学特征。由于ERA儿童和轴向和外周SpA成人的分类标准存在差异，FDA批准了在2020年7月之前自动完全豁免儿童中用于“轴向脊柱关节病，包括强直性脊柱炎”的新药研究。因此，尽管目前的青少年特发性关节炎（JIA）治疗指南建议使用生物疾病缓解抗风湿药物（DMARD）作为ERA患者早期治疗的一部分，但FDA批准的外周SpA或非放射学轴向SpA治疗（赛妥珠单抗、ixekizumab和曲库木单抗）均未研究或标记用于ERA儿童。考虑到成人脊柱关节炎和ERA在病因学、遗传学、发病机制和临床表现方面的相似性，本综述中总结的获批用于轴向SpA或外周SpA的药物也应分别在涉及轴向或外周关节的活动性ERA儿童中进行研究，目的是实现用于儿童的标签。考虑到目前缺乏有效的FDA批准的ERA治疗方法，FDA还应考虑要求对已批准用于治疗SpA成人的药物进行儿科研究。
This review will summarize clinical, genetic and pathophysiologic characteristics that are shared between children with enthesitis related arthritis (ERA) with axial involvement and adults with non-radiographic, and in some cases radiographic, axial spondyloarthritis (SpA); and between children with ERA and primarily peripheral disease manifestations and adults with peripheral SpA. Due to the differences in classification criteria for children with ERA and adults with axial and peripheral SpA, the FDA granted automatic full waivers of studies in children for new medications for “axial spondyloarthropathies including ankylosing spondylitis” up until July 2020. Thus, although current juvenile idiopathic arthritis (JIA) treatment guidelines recommend the use of biologic disease modifying anti-rheumatic drugs (DMARDs) as part of the early treatment for patients with ERA, none of the FDA-approved therapies for peripheral SpA or non-radiographic axial SpA (certolizumab pegol, ixekizumab, and secukinumab) have been studied or are labelled for use in children with ERA. Considering the similarities between adult spondyloarthritis and ERA in terms of etiology, genetics, pathogenesis and clinical manifestations summarized in this review, medications approved for axial SpA or peripheral SpA should also be studied in children with active ERA involving axial or peripheral joints, respectively, with the intent to achieve labeling for use in children. Considering the current lack of effective FDA-approved therapies for ERA, the FDA should also consider requiring pediatric studies for medications that have already been approved for the treatment of adults with SpA.
登录
查看更多内容
影响因子：
27.4
作者：
Carron, Philippe;Varkas, Gaelle;Van den Bosch, Filip
通讯作者：
Van den Bosch, Filip
影响因子：
2.1
作者：
Lee, Edward Y.;Sundel, Robert P.;Kleinman, Paul K.
通讯作者：
Kleinman, Paul K.
影响因子：
4.9
作者：
Gmuca S;Xiao R;Brandon TG;Pagnini I;Wright TB;Beukelman T;Morgan EM;Weiss PF
通讯作者：
Weiss PF
DOI：
10.1186/s12969-018-0238-9
发表时间：
2018-04-02
期刊：
Pediatric rheumatology online journal
影响因子：
--
作者：
Goirand M;Breton S;Chevallier F;Duong NP;Uettwiller F;Melki I;Mouy R;Wouters C;Bader-Meunier B;Job-Deslandre C;Quartier P
通讯作者：
Quartier P
影响因子：
168.9
作者：
Deodhar, Atul;van der Heijde, Desiree;Sieper, Joachim
通讯作者：
Sieper, Joachim